To determine the patient-perceived effectiveness and tolerability of mirabegron compared to solifenacin in a multiple sclerosis (MS) population with overactive bladder (OAB) symptoms.
MS patients with OAB symptoms who were not on medication for their urinary symptoms at enrollment were prospectively recruited.